Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Rating of “Moderate Buy” by Analysts

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have earned an average rating of “Moderate Buy” from the thirteen brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $87.46.

A number of analysts recently commented on RARE shares. Cantor Fitzgerald restated an “overweight” rating and set a $116.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. Canaccord Genuity Group restated a “buy” rating and set a $121.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. HC Wainwright increased their price objective on Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Finally, TD Cowen raised their target price on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, October 21st.

Insider Buying and Selling

In other news, CFO Howard Horn sold 7,465 shares of the business’s stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the sale, the chief financial officer now directly owns 92,301 shares in the company, valued at approximately $4,869,800.76. The trade was a 7.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Emil D. Kakkis sold 8,273 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total transaction of $413,650.00. Following the transaction, the chief executive officer now directly owns 2,195,712 shares in the company, valued at approximately $109,785,600. This represents a 0.38 % decrease in their position. The disclosure for this sale can be found here. 5.80% of the stock is owned by company insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Several hedge funds have recently added to or reduced their stakes in RARE. Wilmington Savings Fund Society FSB purchased a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth about $83,000. Geode Capital Management LLC lifted its position in Ultragenyx Pharmaceutical by 4.4% in the third quarter. Geode Capital Management LLC now owns 1,571,081 shares of the biopharmaceutical company’s stock valued at $87,296,000 after purchasing an additional 65,623 shares during the last quarter. M&T Bank Corp lifted its position in Ultragenyx Pharmaceutical by 8.1% in the third quarter. M&T Bank Corp now owns 6,992 shares of the biopharmaceutical company’s stock valued at $388,000 after purchasing an additional 525 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its stake in shares of Ultragenyx Pharmaceutical by 49.1% during the third quarter. Frazier Life Sciences Management L.P. now owns 633,715 shares of the biopharmaceutical company’s stock valued at $35,203,000 after purchasing an additional 208,715 shares during the period. Finally, Nomura Asset Management Co. Ltd. bought a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth approximately $93,000. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE opened at $45.78 on Friday. Ultragenyx Pharmaceutical has a 1 year low of $37.02 and a 1 year high of $60.37. The stock’s fifty day moving average price is $50.47 and its two-hundred day moving average price is $49.15. The firm has a market cap of $4.23 billion, a PE ratio of -7.08 and a beta of 0.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. The business had revenue of $139.49 million for the quarter, compared to analysts’ expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The firm’s quarterly revenue was up 42.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($2.23) EPS. Sell-side analysts anticipate that Ultragenyx Pharmaceutical will post -6.2 earnings per share for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.